Ocular Therapeutix to Unveil Key SOL-1 Trial Data for Wet AMD Treatment
Event summary
- Ocular Therapeutix will present detailed SOL-1 Phase 3 trial results for AXPAXLI (OTX-TKI) in wet AMD at the 49th Macula Society Annual Meeting on February 27, 2026.
- An investor webcast to discuss the data is scheduled for March 2, 2026, at 7:30 AM ET.
- SOL-1 Symposium slides will be filed with the SEC and made available on Ocular's website.
- AXPAXLI is Ocular's investigational product candidate for retinal diseases, leveraging its ELUTYX hydrogel technology.
The big picture
Ocular Therapeutix's presentation of SOL-1 data is a critical milestone in the development of AXPAXLI, a potential game-changer in the treatment of wet AMD. The success of this trial could position Ocular as a key player in the retinal disease market, competing with established therapies. The broader implications include the potential expansion of the ELUTYX technology platform into other retinal diseases, such as diabetic retinopathy.
What we're watching
- Clinical Efficacy
- How the detailed SOL-1 data will position AXPAXLI against existing wet AMD treatments in terms of efficacy and safety.
- Regulatory Pathway
- Whether the trial results will accelerate or complicate the regulatory approval process for AXPAXLI.
- Market Adoption
- The pace at which Ocular Therapeutix can secure partnerships or commercial agreements based on the trial outcomes.
Related topics